Celgene (NASDAQ:CELG)

Biotechnology word cloud

Who Bucked the Short Interest Trend in Biotech Stocks?

24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. Many biotech stocks pulled back in late March, and short sellers moved in on many ...
Read Full Story »
research

Credit Suisse Says Grit Your Teeth and Buy Biotech

For the second time since late February, a huge run on the momentum, and specifically biotech, names hit the market last week. Again, the biotech benchmark took a huge 4% ...
Read Full Story »
Biotechnology word cloud

Stifel Says Strong Earnings Will Reignite Biotech Rally

When the biotech sell-off started in late February, the stocks had been market leaders for almost four years. The staggering and intense selling knocked a quick 17% off the index ...
Read Full Story »
Stock Split Image

Biotech Giants Now Priced Like Old World Drug Stocks

Most investors buying Big Pharma stocks these days are buying them for dividends and somewhat of a defensive position against stock market volatility. Investors who are buying biotechs generally are ...
Read Full Story »
DNA

Large Cap Biotechs Trading With Only Big Pharma P/E Ratios

The iShares Nasdaq Biotechnology (NASDAQ: IBB) exchange traded fund (ETF) has pulled back almost 17% since the February 25 peak, in a sell-off likened to the August 2011 debacle. Trading ...
Read Full Story »
Morgan Stanley logo

Morgan Stanley Starts Mixed Coverage on Top Biotech Stocks

Like many of its Wall Street peers, the brutal sell-off in the biotechnology space has Morgan Stanley taking a closer look at the top names. The firm initiated coverage of ...
Read Full Story »
Biotechnology word cloud

Short Sellers Find Renewed Interest in Biotech Stocks

24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. After retreating from many of these stocks in the previous two periods, short sellers returned ...
Read Full Story »
West side view of the United States Capitol building.

Top Biotechnology Stocks On Sale Again

For the second time in less than a month, the biotechnology sector got whacked when once again, chatter coming from the halls of Congress over drug pricing concerns hit the ...
Read Full Story »
Biotechnology word cloud

Short Sellers Retreat From Biotech Stocks Again

24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. Stocks in this industry continue to be hot, but short sellers shied away from many ...
Read Full Story »
Biotechnology word cloud

Short Sellers Return to Biotech Stocks

24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. After largely shying away in the previous period, short sellers returned to many of these ...
Read Full Story »
Biotechnology word cloud

Short Sellers Shy Away From Biotechs

24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. By and large, short sellers shied away from these stocks in late January. The largest ...
Read Full Story »
DNA

Why Caution Is Prevailing in Biotechs Into and After Earnings

Biotechnology stocks struggled on Wednesday after Biogen Idec Inc. (NASDAQ: BIIB) surprised investors with weaker-than-expected guidance for 2014 earnings. The struggles also may be due to simple profit-taking. Stocks in ...
Read Full Story »
Biotechnology word cloud

UBS Says Buy Top Biotech Stocks in Front of Earnings for Big Upside

Like many firms on Wall Street, the biotechnology team at UBS thinks that most of the top mega-cap and large cap biotech stocks are poised to beat earnings estimates across ...
Read Full Story »
biotech

Cowen Top Biotech Stocks to Buy for 2014 With Huge Upside

Anybody that has been long the biotechnology sector for the past four years has had outstanding returns. Following four straight years of outperformance against the S&P 500, investor interest in ...
Read Full Story »
biotech

Higher 2017 Celgene Guidance Keeps Confusion in Near-Term

Celgene Corp. (NASDAQ: CELG) has been one of the top performing biotech giants of late, and now we have some confusing guidance for 2013, 2014 and 2015. The company has ...
Read Full Story »